摘要
目的:探讨正肝化症汤联合艾迪注射液对原发性肝癌患者肝功能的影响。方法:选取2015年10月至2017年4月海南省中医院收治的原发性肝癌患者76例作为研究对象,按照随机数字表法随机分为对照组和观察组,每组38例。对照组采取肝动脉化疗栓塞术(TACE)治疗,观察组在对照组基础上加用艾迪注射液+正肝化症汤,持续治疗1个月。统计2组临床疗效、入院时及疗程结束后免疫功能指标(CD3^+、CD4^+、CD8^+、CD4^+/CD8^+)水平、肝功能指标[总胆红素(TBil)、天冬氨酸氨基转移酶(AST)、谷氨酸氨基转移酶(ALT)]水平、生命质量(EORTC QLQ-30)评分、血清甲胎蛋白(AFP)、癌胚抗原(CEA)水平。结果:观察组总有效率(89.47%)高于对照组(71.05%),差异有统计学意义(P<0.05);治疗前2组血清CD3^+、CD4^+、CD8^+、CD4^+/CD8^+水平间比较,差异无统计学意义(P>0.05),治疗后观察组血清CD3^+、CD4^+、CD8^+、CD4^+/CD8^+水平改善幅度大于对照组,CD8^+水平较对照组低,差异有统计学意义(P<0.05)。治疗前2组血清TBil、AST、ALT水平间差异无统计学意义(P>0.05),治疗后与对照组比较,观察组血清TBil、AST、ALT等肝功能指标水平均明显降低,差异有统计学意义(P<0.05)。与对照组比较,治疗后2组EORTC QLQ-30分值明显升高,差异有统计学意义(P<0.05)。治疗前2组血清AFP及CEA水平比较,差异无统计学意义(P>0.05),治疗后2组血清AFP及CEA水平较治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05)。结论:常规治疗基础上联合采取艾迪注射液及正肝化症汤对原发性肝癌患者进行联合干预,可有效改善其肝功能,调节机体免疫功能,降低血清肿瘤标志物AFP及CEA表达水平,提高治疗效果,恢复患者生命质量。
Objective:To investigate the effects of Zhenggan Huazheng Decoction combined with Aidi injection on the liver function of patients with primary liver cancer.Methods:A total of 66 patients with primary liver cancer from October 2015 to April 2017 were enrolled in Hainan Provincial Hospital of TCM and were randomly divided into a control group and an observation group according to random number table,with 38 cases in each group.The control group was treated with transcatheter arterial chemoembolization(TACE),and the study group was treated with Addie injection+Zhenggan Huazheng Decoction on the basis of the control group.Both groups were treated for 1 month continuously.The clinical curative effect,immune function indexes(CD3^+,CD4^+,CD8^+,CD4^+/CD8^+),liver function indexes[total bilirubin(TBil),aspartate aminotransferase(AST),glutamate aminotransferase(ALT)],alpha fetoprotein(AFP),carcinoembryonic antigen(CEA)and quality of life(EORTC QLQ-30)score at the time of admission and after the end of the course of the 2 groups were statistically recorded.Results:The total effective rate of the study group(89.47%)was higher than that of the control group(71.05%),and the difference was statistically significant(P<0.05).There was no significant difference in serum CD3^+,CD4^+,CD8^+,CD4^+/CD8^+levels between the 2 groups before treatment(P>0.05).After treatment,the serum CD3^+,CD4^+,CD8^+,CD4^+/CD8^+levels in the study group improved more than the control group,and the CD8^+level was lower than the control group,with significant difference(P<0.05).There was no significant difference in serum TBil,AST and ALT levels between the 2 groups before treatment(P>0.05).After treatment,compared with the control group,the serum levels of TBil,AST,ALT and other liver function indexes in the study group were significantly decreased,and the difference was statistically significant(P<0.05).Compared with the control group,the EORTC QLQ-30 scores in the 2 groups were significantly increased after treatment,and the difference was statistically significant(P<0.05).There was no significant difference in serum AFP and CEA levels between the 2 groups before treatment(P>0.05).After treatment,serum AFP and CEA levels were decreased than before treatment,and the study group was lower than the control group.The difference was statistically significant(P<0.05).Conclusion:On the basis of routine treatment,the combined intervention of Addie injection and Zhenggan Huazheng Decoction on patients with primary liver cancer can effectively improve their liver function,regulate the immune function,reduce serum tumor markers AFP and CEA expression,improve the therapeutic effect and restore the quality of life of patients.
作者
邢明远
黄清云
苏乙花
Xing Mingyuan;Huang Qingyun;Su Yihua(Department of Oncology,Hainan Provincial Hospital of TCM,Haikou 570203,China)
出处
《世界中医药》
CAS
2019年第11期2983-2987,共5页
World Chinese Medicine
基金
海南省2019-2021年省级中医重点专科建设项目(肿瘤科)(S100111.401)
关键词
正肝化症汤
艾迪注射液
原发性肝癌
肝功能
Zhenggan Huazheng Decoction
Addie Injection
Primary liver cancer
Liver function
